WO2000041684A1 - A pharmaceutical combination for the treatment of depression - Google Patents
A pharmaceutical combination for the treatment of depression Download PDFInfo
- Publication number
- WO2000041684A1 WO2000041684A1 PCT/US1999/029590 US9929590W WO0041684A1 WO 2000041684 A1 WO2000041684 A1 WO 2000041684A1 US 9929590 W US9929590 W US 9929590W WO 0041684 A1 WO0041684 A1 WO 0041684A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- combination
- fluoxetine
- igmesine
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- Fluoxetine hydrochloride a marketed antidepressant known as Prozac, of chemical structure
- Igmesine a drug useful for depression, of chemical structure
- the compound (l-propyl-5-(3-p-tolyl-isoxazol-5-yl)-l, 2,3 ,6-tetrahydro- pyridine), sigma receptor ligand, is taught in United States Patent 5,330,994 which is hereby incorporated by reference.
- the compound (3-phenyl-l-(l-propryl- l,2,5,6-tetrahydro-pyridin-3-yl)-propan-l-one oxime) is another sigma receptor ligand and is taught in United States Patents 4,798,841; 5,073,561 ; and 4,929,734 which are hereby incorporated by reference.
- the instant invention is a new method for treating depression in a mammal in need thereof which comprises administering a combination of a sigma receptor ligand and a serotonin reuptake inhibitor.
- Sigma receptor ligands useful in the treatment are selected from
- SKF- 10,047 dextromethorphan, haloperidol, elipiodil, BMY- 14802, igmesine, JO-1994, NPC-16377, l-propyl-5-(3-p-tolyl-isoxazol-5-yl)-l,2,3,6-tetrahydro- pyridine, and 3-phenyl-l-(l-propryl-l,2,5,6-tetrahydro-pyridin-3-yl)-propan-l-one oxime.
- Serotonin reuptake inhibitors are selected from: fluoxetine, venlafaxine, citalopram, fluvoxamine, paroxetine, sertraline, milnacipran, and duloxetine. Pharmaceutically acceptable salts of the compounds are also useful.
- igmesine The combination of igmesine and fluoxetine is particularly useful.
- the combinations of the invention are useful in treating depression, especially refractory depression.
- Figure 1 shows the effect of igmesine-fluoxetine combination in the Behavioral Despair Test in rats.
- Figure 2 shows the effect of igmesine and fluoxetine in the Tail Suspension Test in mice.
- the instant invention is a combination of the two antidepressants to provide solutions to several problems encountered in the current treatments of patients suffering from depression.
- One of the most outstanding advantages to the patient of the invention is the faster onset of action provided by the combination as compared to either a serotonin reuptake inhibitor or a sigma receptor ligand alone. Since there is a shorter interval for the effect to be felt, the patient is at less risk of suicide. - About 15% of the patient population does not respond to any of the current drug therapies as it suffers from refractory depression. The instant combination provides an answer for these patients and for others suffering from depression. The two known compounds act in the body in two distinct and different mechanisms. The combination of a serotonin reuptake inhibitor and a sigma receptor ligand provides a potentiated effect.
- the combination has fewer undesired side effects partly because the individual compounds can be administered in lower doses. This leads to better patient compliance since the patient experiences enhanced relief.
- the protocol useful in the testing of a sigma receptor ligand in combination with a serotonin reuptake inhibitor is as follows.
- Patients suffering from Depressive Disorder who have symptoms of at least moderate severity, as judged clinically, are administered in a double-blind, randomized fashion, either igmesine alone, fluoxetine alone, or the combination thereof for a period of no less than 4 weeks and possibly as long as 8 weeks.
- Combination treatment with igmesine and fluoxetine is more beneficial than fluoxetine alone in the treatment of patients whose depressive illness is refractory to previous drug therapy. This benefit is demonstrated by treating patients with fluoxetine for 8 weeks. All those whose depression is not relieved are randomized in a double-blind manner to treatment with either fluoxetine alone or a combination of fluoxetine and igmesine. The combination is expected to be more effective in relieving depressive symptoms than the continuation of fluoxetine alone.
- the unit doses used for antidepressants are usually between 1 and 500 mg, and more particularly between 5 and 200 mg product, depending on the nature and the severity of the condition to be treated.
- the daily therapeutic doses can be divided into several administrations and are between 5 and 2,000 mg product per day.
- a daily dosage of 50 to 500 mg product per day divides into 2 to 4 administrations is generally sufficient.
- the products according to the instant invention are administered to patients in a form of medicaments suitable for the condition to be treated.
- the preparations will be, for example, tablets, coated tablets, capsules, powders, solutions, suspensions, gels, or suppositories, depending on the case.
- the pharmaceutical forms are prepared from the products in the form of the base or their salts and in accordance with the methods usually employed in this industry.
- the active principle In medicament forms of a solid nature, the active principle generally makes up 5% to 90% by weight of the total finished form, and the medicaments thus make up 95% to 10%.
- the amount of active principle is between 0.1% and 10% by weight of the finished form, and the excipient can thus make up 99.9% to 90% by weight of this form.
- the compounds of this invention can be given orally or parenterally; oral dosing is preferred. In either instance, it is preferred to use an acid addition salt of the compound formed with a pharmaceutically-acceptable nontoxic acid.
- the salt can be mixed with standard pharmaceutical excipients and placed in telescoping gelatin capsules.
- the compound can be mixed with starch, binders, etc. and formulated into tablets, which tablets may be scored for ease of divided dosage administration.
- a water soluble salt of the compound of this invention, which salt is pharmaceutically-acceptable is dissolved in an isotonic solution and administered intramuscularly, intravenously, or subcutaneously.
- the oral pharmaceutical forms are naturally preferred.
- the dose level should vary from 1- to 50-mg/dose given from 1 to 4 times a day with a total daily dosage of 1 to 200 mg/day/human. Rather than a dose of from 20 to 80 mg per day of fluoxetine, the combination of the instant inventions uses as little as 10 mg of the drug. Rather than a dose of from 25 to 100 mg per day of igmesine, as low a dose as 25 mg can be given. A skilled physician will adjust dose levels as needed. Behavioral Tests
- igmesine and fluoxetine were evaluated in the mouse Tail Suspension Test and the rat Swim Despair Test. In both of these tests, higher doses of igmesine and fluoxetine, when administered alone, were needed to produce antidepressant-like effects.
- rats were placed in a small tank of water for 15 minutes. Initially, the animals swam, but could not escape so they stopped swimming. Immediately after the swim session the rats were injected with vehicle or a dose of the test compound. The next day, approximately 24 hours after the first swim session, the animals were injected with vehicle or the test compounds at a specified time prior to the second swim session. The rats were again placed in the water tank. They had learned from the first day that the could not escape the water, so they had very little activity. Revolutions of a wire wheel at the water-air interface, at which the rat directs its activity, was used to quantify the activity of the animal in the tank. This test has been demonstrated to predict antidepressant- like activity.
- Figure 1 shows the effect of igmesine (I) and fluoxetine (F) in combination in the Behavioral Despair Test in Wistar-Kyoto rats.
- Saline is S.
- the wheel rotations are for 5 minutes total, and the dose is in milligrams per kilograms given IP.
- the mean is ⁇ SEM; the number was 35-36/group. It is clear from Figure 1 that neither compound alone differs from the vehicle, and that a combination of the two ineffective doses was more than three times as effective.
- Figure 2 shows the effect of igmesine and fluoxetine in the Tail Suspension Test in CD-I mice. The immobility is given in seconds and the dose in milligrams per kilograms given IP.
- mice were gently suspended by its tail to a force transducer which measured the amount of time the animal struggled. Normally, the mouse struggled for awhile and then quietly hung there. Antidepressants increase the amount of time the mice attempt to escape.
- igmesine and fluoxetine at doses which by themselves did not produce an antidepressant-like effect, when given in combination, produced an antidepressant-like effect, as evidenced by a decrease in the immobility time in a 6-minute test (see Figure 1).
- This dose combination of 2 inactive doses of 2 different compounds provided antidepressant-like behavioral effects.
- igmesine increases the release of dopamine and norepinephrine while fluoxetine and other SSRIs increase the release of serotonin.
- igmesine and fluoxetine in combination lead to an enhanced release of all 3 transmitters, to a greater degree than low doses of either agent alone.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The instant invention is a method for the treatment of depression, especially refractory depression, which comprises administering a combination of a sigma receptor ligand and a serotonin reuptake inhibitor.
Description
A PHARMACEUTICAL COMBINATION FOR THE TREATMENT
OF DEPRESSION
BACKGROUND OF THE INVENTION
Fluoxetine hydrochloride, a marketed antidepressant known as Prozac, of chemical structure
is a serotonin reuptake inhibitor. The compound is taught in United States Patent 4,314,081 which is hereby incorporated by reference.
Igmesine, a drug useful for depression, of chemical structure
has a particular binding affinity for sigma receptors. The chemical name is trans-+-N-cyclopropylmethyl-N-( 1 ,4-diphenyl- 1 -ethyl-3-buten- 1 -yl)- N-methylamine hydrochloride salt. The compound is taught in United States Patent 5,034,419 which is hereby incorporated by reference.
The compound (l-propyl-5-(3-p-tolyl-isoxazol-5-yl)-l, 2,3 ,6-tetrahydro- pyridine), sigma receptor ligand, is taught in United States Patent 5,330,994 which is hereby incorporated by reference. The compound (3-phenyl-l-(l-propryl- l,2,5,6-tetrahydro-pyridin-3-yl)-propan-l-one oxime) is another sigma receptor ligand and is taught in United States Patents 4,798,841; 5,073,561 ; and 4,929,734 which are hereby incorporated by reference.
SUMMARY OF THE INVENTION
The instant invention is a new method for treating depression in a mammal in need thereof which comprises administering a combination of a sigma receptor ligand and a serotonin reuptake inhibitor. Sigma receptor ligands useful in the treatment are selected from
SKF- 10,047, dextromethorphan, haloperidol, elipiodil, BMY- 14802, igmesine, JO-1994, NPC-16377, l-propyl-5-(3-p-tolyl-isoxazol-5-yl)-l,2,3,6-tetrahydro- pyridine, and 3-phenyl-l-(l-propryl-l,2,5,6-tetrahydro-pyridin-3-yl)-propan-l-one oxime. Serotonin reuptake inhibitors (SSRI) are selected from: fluoxetine, venlafaxine, citalopram, fluvoxamine, paroxetine, sertraline, milnacipran, and duloxetine. Pharmaceutically acceptable salts of the compounds are also useful.
The combination of igmesine and fluoxetine is particularly useful.
The combinations of the invention are useful in treating depression, especially refractory depression.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the effect of igmesine-fluoxetine combination in the Behavioral Despair Test in rats.
Figure 2 shows the effect of igmesine and fluoxetine in the Tail Suspension Test in mice.
DETAILED DESCRIPTION OF THE INVENTION
The instant invention is a combination of the two antidepressants to provide solutions to several problems encountered in the current treatments of patients suffering from depression.
One of the most outstanding advantages to the patient of the invention is the faster onset of action provided by the combination as compared to either a serotonin reuptake inhibitor or a sigma receptor ligand alone. Since there is a shorter interval for the effect to be felt, the patient is at less risk of suicide.
- About 15% of the patient population does not respond to any of the current drug therapies as it suffers from refractory depression. The instant combination provides an answer for these patients and for others suffering from depression. The two known compounds act in the body in two distinct and different mechanisms. The combination of a serotonin reuptake inhibitor and a sigma receptor ligand provides a potentiated effect.
The combination has fewer undesired side effects partly because the individual compounds can be administered in lower doses. This leads to better patient compliance since the patient experiences enhanced relief. The protocol useful in the testing of a sigma receptor ligand in combination with a serotonin reuptake inhibitor is as follows.
Patients suffering from Depressive Disorder who have symptoms of at least moderate severity, as judged clinically, are administered in a double-blind, randomized fashion, either igmesine alone, fluoxetine alone, or the combination thereof for a period of no less than 4 weeks and possibly as long as 8 weeks.
During this treatment period, patients are frequently assessed for changes in the severity of depressive symptoms using standard, and commonly utilized rating scales, such as the Hamilton Depression Scale or the Montgomery-Asberg Depression Scale. This method provides a side-by-side comparison of the effects of either drug alone with the combination. Thereby, it can be demonstrated that the combination provides superior antidepressant therapeutic effects than either drug alone.
Combination treatment with igmesine and fluoxetine is more beneficial than fluoxetine alone in the treatment of patients whose depressive illness is refractory to previous drug therapy. This benefit is demonstrated by treating patients with fluoxetine for 8 weeks. All those whose depression is not relieved are randomized in a double-blind manner to treatment with either fluoxetine alone or a combination of fluoxetine and igmesine. The combination is expected to be more effective in relieving depressive symptoms than the continuation of fluoxetine alone.
The unit doses used for antidepressants are usually between 1 and 500 mg, and more particularly between 5 and 200 mg product, depending on the nature and the severity of the condition to be treated. The daily therapeutic doses can be
divided into several administrations and are between 5 and 2,000 mg product per day. A daily dosage of 50 to 500 mg product per day divides into 2 to 4 administrations is generally sufficient.
The products according to the instant invention are administered to patients in a form of medicaments suitable for the condition to be treated. The preparations will be, for example, tablets, coated tablets, capsules, powders, solutions, suspensions, gels, or suppositories, depending on the case. The pharmaceutical forms are prepared from the products in the form of the base or their salts and in accordance with the methods usually employed in this industry. In medicament forms of a solid nature, the active principle generally makes up 5% to 90% by weight of the total finished form, and the medicaments thus make up 95% to 10%. For liquid forms, which can be considered as such, the amount of active principle is between 0.1% and 10% by weight of the finished form, and the excipient can thus make up 99.9% to 90% by weight of this form. In treating humans suffering from various psychoses having a depressive component, the compounds of this invention can be given orally or parenterally; oral dosing is preferred. In either instance, it is preferred to use an acid addition salt of the compound formed with a pharmaceutically-acceptable nontoxic acid. For purposes of oral administration, the salt can be mixed with standard pharmaceutical excipients and placed in telescoping gelatin capsules. Similarly, the compound can be mixed with starch, binders, etc. and formulated into tablets, which tablets may be scored for ease of divided dosage administration. For parenteral administration, a water soluble salt of the compound of this invention, which salt is pharmaceutically-acceptable, is dissolved in an isotonic solution and administered intramuscularly, intravenously, or subcutaneously. For chronic administration, the oral pharmaceutical forms are naturally preferred. The dose level should vary from 1- to 50-mg/dose given from 1 to 4 times a day with a total daily dosage of 1 to 200 mg/day/human. Rather than a dose of from 20 to 80 mg per day of fluoxetine, the combination of the instant inventions uses as little as 10 mg of the drug. Rather than a dose of from 25 to 100 mg per day of igmesine, as low a dose as 25 mg can be given. A skilled physician will adjust dose levels as needed.
Behavioral Tests
The interaction of igmesine, or other sigma ligands, and fluoxetine, or other SSRIs, to produce antidepressant-like activity in preclinical tests is evaluated in the mouse Tail Suspension Test and rat Swim Despair Test, well- recognized animal tests to predict clinical antidepressant activity.
The interaction of igmesine and fluoxetine, at doses which by themselves are inactive in producing antidepressant-like activity in preclinical, were evaluated in the mouse Tail Suspension Test and the rat Swim Despair Test. In both of these tests, higher doses of igmesine and fluoxetine, when administered alone, were needed to produce antidepressant-like effects.
Forced Swim Behavioral Despair Test in Rats
On Day 1 of the experiment, rats were placed in a small tank of water for 15 minutes. Initially, the animals swam, but could not escape so they stopped swimming. Immediately after the swim session the rats were injected with vehicle or a dose of the test compound. The next day, approximately 24 hours after the first swim session, the animals were injected with vehicle or the test compounds at a specified time prior to the second swim session. The rats were again placed in the water tank. They had learned from the first day that the could not escape the water, so they had very little activity. Revolutions of a wire wheel at the water-air interface, at which the rat directs its activity, was used to quantify the activity of the animal in the tank. This test has been demonstrated to predict antidepressant- like activity.
In these experiments igmesine and fluoxetine, at doses which by themselves did not produce an antidepressant-like effect, when given in combination, produced an antidepressant-like effect, as evidenced by an increase in the number of wheel rotations in the first 5 minutes of the test (see Figure 1).
Figure 1 shows the effect of igmesine (I) and fluoxetine (F) in combination in the Behavioral Despair Test in Wistar-Kyoto rats. Saline is S. The wheel rotations are for 5 minutes total, and the dose is in milligrams per kilograms given IP. The mean is ±SEM; the number was 35-36/group. It is clear from Figure 1 that neither compound alone differs from the vehicle, and that a combination of the two ineffective doses was more than three times as effective.
Figure 2 shows the effect of igmesine and fluoxetine in the Tail Suspension Test in CD-I mice. The immobility is given in seconds and the dose in milligrams per kilograms given IP.
The data show that subthreshold doses of the compound, when given in combination, provide an antidepressant effect.
In the mouse Tail Suspension Test model, a mouse was gently suspended by its tail to a force transducer which measured the amount of time the animal struggled. Normally, the mouse struggled for awhile and then quietly hung there. Antidepressants increase the amount of time the mice attempt to escape. In these experiments, igmesine and fluoxetine, at doses which by themselves did not produce an antidepressant-like effect, when given in combination, produced an antidepressant-like effect, as evidenced by a decrease in the immobility time in a 6-minute test (see Figure 1).
In these studies, a dose-response for both igmesine and fluoxetine was determined. Then inactive doses of each agent were administered simultaneously.
This dose combination of 2 inactive doses of 2 different compounds provided antidepressant-like behavioral effects.
Neurochemical Tests
In neurochemical tests in rats, igmesine increases the release of dopamine and norepinephrine while fluoxetine and other SSRIs increase the release of serotonin. Using relatively low doses of each agent, igmesine and fluoxetine, in combination lead to an enhanced release of all 3 transmitters, to a greater degree than low doses of either agent alone.
The following example is for illustration purposes.
Tablets
Fluoxetine 10 mg
Igmesine 20 mg
Polyvinylpyrrolidone 20 mg
Carboxymethyl starch 8.0 mg
Magnesium stearate 2.0 mg
Colloidal silica 0.4 mg
Lactose in a sufficient amount -200.0 mg
Claims
1. A method for treating depression in a mammal in need thereof which comprises administering a combination of a sigma receptor ligand and a serotonin reuptake inhibitor.
2. A method of treatment according to Claim 1 wherein the combination is a sigma receptor ligand selected from: SKF-10,047, dextromethorphan, haloperidol, elipiodil, BMY- 14802, igmesine, JO- 1994, NPC-16377, (3-phenyl-l -(1 -propryl-1 ,2,5,6-tetrahydro-pyridin-3-yl)-propan-l -one oxime) or (l-propyl-5-(3-p-tolyl-isoxazol-5-yl)-l, 2,3, 6-tetrahydro- pyridine), and a serotonin reuptake inhibitor selected from: fluoxetine, venlafaxine, citalopram, fluvoxamine, paroxetine, duloxetine, sertraline, or milnacipran, or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical agent which is a combination of a sigma receptor ligand and a serotonin reuptake inhibitor.
4. A combination according to Claim 3 of a sigma receptor ligand selected from: SKF- 10,047, dextromethorphan, haloperidol, elipiodil, BMY- 14802, igmesine, JO- 1994, and NPC-16377 and a serotonin reuptake inhibitor selected from: fluoxetine, venlafaxine, citalopram, fluvoxamine, duloxetine, paroxetine, sertraline, and milnacipran, or a pharmaceutically acceptable salt thereof.
5. A method for treating depression in a mammal in need thereof which comprises administering igmesine or a pharmaceutically acceptable salt thereof and fluoxetine or a pharmaceutically acceptable salt thereof in a pharmaceutical composition.
6. A method for treating refractory depression in a mammal in need thereof which comprises administering igmesine or a pharmaceutically acceptable salt thereof and fluoxetine or a pharmaceutically acceptable salt thereof in a pharmaceutical composition.
7. A method for treating depression in a human subject in need of such treatment which comprises the administration to said human a therapeutically effective amount of fluoxetine or norfiuoxetine or a pharmaceutically acceptable salt thereof in combination which igmesine or a pharmaceutically acceptable salt thereof.
8. A method according to Claim 7 wherein the combination is administered orally.
9. A method according to Claim 7 wherein the fluoxetine and the igmesine are administered as the hydrochloride salt.
10. A method according to Claim 7 in which the daily dosage level of fluoxetine is 8 to 10 mg and igmesine is 15 to 20 mg.
11. A method of treating depression in a human in need of such therapy by administering an effective amount of R(-)fiuoxetine or a pharmaceutically acceptable salt thereof, substantially free of its S(+)stereoisomer in combination with a compound with binding affinity for the sigma receptor.
12. A method of treating depression in a human in need of such therapy by administering S(+) fluoxetine in combination with a compound with binding affinity for the sigma receptor.
13. A method according to Claim 1 1 wherein the compound with binding affinity for the sigma receptor is igmesine or a pharmaceutically acceptable salt thereof.
14. A method for increasing or enhancing the release of 3 transmitters: dopamine, norepinephrine, and serotonin in the brain comprising administering a combination of a compound with binding affinity for the sigma receptor and a serotonin reuptake inhibitor.
15. A method according to Claim 14 wherein the amount of the compound with binding affinity of the sigma receptor is between 15 and 20 mg and the amount of the SSRI compound is between 8 and 10 mg.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU21804/00A AU2180400A (en) | 1999-01-13 | 1999-12-14 | A pharmaceutical combination for the treatment of depression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11565999P | 1999-01-13 | 1999-01-13 | |
US60/115,659 | 1999-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000041684A1 true WO2000041684A1 (en) | 2000-07-20 |
Family
ID=22362703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/029590 WO2000041684A1 (en) | 1999-01-13 | 1999-12-14 | A pharmaceutical combination for the treatment of depression |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2180400A (en) |
WO (1) | WO2000041684A1 (en) |
Cited By (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1224930A1 (en) * | 2001-01-22 | 2002-07-24 | Pfizer Products Inc. | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression |
US9168234B2 (en) | 2013-11-05 | 2015-10-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9198905B2 (en) | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
US9408815B2 (en) | 2013-11-05 | 2016-08-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9457023B1 (en) | 2013-11-05 | 2016-10-04 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9457025B2 (en) | 2013-11-05 | 2016-10-04 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
US9474731B1 (en) | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9700528B2 (en) | 2013-11-05 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9707191B2 (en) | 2013-11-05 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
WO2017137600A1 (en) | 2016-02-11 | 2017-08-17 | Sigmathera Sas | Igmesine for use in the treatment of neurodegenerative diseases |
US9763932B2 (en) | 2013-11-05 | 2017-09-19 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9861595B2 (en) | 2013-11-05 | 2018-01-09 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9867819B2 (en) | 2013-11-05 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9968568B2 (en) | 2013-11-05 | 2018-05-15 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10058518B2 (en) | 2013-11-05 | 2018-08-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10080727B2 (en) | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10092561B2 (en) | 2013-11-05 | 2018-10-09 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
US10105361B2 (en) | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10105327B2 (en) | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
US10512643B2 (en) | 2013-11-05 | 2019-12-24 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US10688066B2 (en) | 2018-03-20 | 2020-06-23 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for treating nicotine addiction |
US10772850B2 (en) | 2013-11-05 | 2020-09-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10780064B2 (en) | 2019-01-07 | 2020-09-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10786469B2 (en) | 2013-11-05 | 2020-09-29 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10799497B2 (en) | 2013-11-05 | 2020-10-13 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
US10813924B2 (en) | 2018-03-20 | 2020-10-27 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for treating nicotine addiction |
US10864209B2 (en) | 2013-11-05 | 2020-12-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10874663B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10874664B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10874665B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10881657B2 (en) | 2013-11-05 | 2021-01-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10894046B2 (en) | 2013-11-05 | 2021-01-19 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10894047B2 (en) | 2013-11-05 | 2021-01-19 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10898453B2 (en) | 2013-11-05 | 2021-01-26 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10925842B2 (en) | 2019-01-07 | 2021-02-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10933034B2 (en) | 2013-11-05 | 2021-03-02 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10940124B2 (en) | 2019-01-07 | 2021-03-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10945973B2 (en) | 2013-11-05 | 2021-03-16 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10966941B2 (en) | 2013-11-05 | 2021-04-06 | Antecip Bioventures Ii Llp | Bupropion as a modulator of drug activity |
US10966942B2 (en) | 2019-01-07 | 2021-04-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10966974B2 (en) | 2013-11-05 | 2021-04-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10980800B2 (en) | 2013-11-05 | 2021-04-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11007189B2 (en) | 2013-11-05 | 2021-05-18 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11020389B2 (en) | 2013-11-05 | 2021-06-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11058648B2 (en) | 2013-11-05 | 2021-07-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11065248B2 (en) | 2013-11-05 | 2021-07-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11090300B2 (en) | 2013-11-05 | 2021-08-17 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11096937B2 (en) | 2013-11-05 | 2021-08-24 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11123343B2 (en) | 2013-11-05 | 2021-09-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11123344B2 (en) | 2013-11-05 | 2021-09-21 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
US11129826B2 (en) | 2013-11-05 | 2021-09-28 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
US11141388B2 (en) | 2013-11-05 | 2021-10-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11141416B2 (en) | 2013-11-05 | 2021-10-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11147808B2 (en) | 2013-11-05 | 2021-10-19 | Antecip Bioventures Ii Llc | Method of decreasing the fluctuation index of dextromethorphan |
US11185515B2 (en) | 2013-11-05 | 2021-11-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11213521B2 (en) | 2013-11-05 | 2022-01-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
US11234946B2 (en) | 2013-11-05 | 2022-02-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11253492B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11253491B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11273134B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11273133B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11285146B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11291638B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11311534B2 (en) | 2013-11-05 | 2022-04-26 | Antecip Bio Ventures Ii Llc | Bupropion as a modulator of drug activity |
US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11517542B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
US5034419A (en) * | 1988-09-01 | 1991-07-23 | L'oreal | N-cycloalkylalkylamines, process for their preparation, their use as medicament and their synthesis intermediates |
WO1996009044A1 (en) * | 1994-09-22 | 1996-03-28 | Richard Alan Smith | Compositions useful for the preparation of medicines for treating a variety of intractable disorders |
US5922341A (en) * | 1997-10-28 | 1999-07-13 | Vivus, Incorporated | Local administration of pharmacologically active agents to treat premature ejaculation |
-
1999
- 1999-12-14 AU AU21804/00A patent/AU2180400A/en not_active Abandoned
- 1999-12-14 WO PCT/US1999/029590 patent/WO2000041684A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4314081A (en) * | 1974-01-10 | 1982-02-02 | Eli Lilly And Company | Arloxyphenylpropylamines |
US5034419A (en) * | 1988-09-01 | 1991-07-23 | L'oreal | N-cycloalkylalkylamines, process for their preparation, their use as medicament and their synthesis intermediates |
WO1996009044A1 (en) * | 1994-09-22 | 1996-03-28 | Richard Alan Smith | Compositions useful for the preparation of medicines for treating a variety of intractable disorders |
US5922341A (en) * | 1997-10-28 | 1999-07-13 | Vivus, Incorporated | Local administration of pharmacologically active agents to treat premature ejaculation |
Non-Patent Citations (1)
Title |
---|
MIN-SOO LEE ET AL.: "Co-administration of sertraline and haloperidol", PSYCHIATRY AND CLINICAL NEUROSCIENCES, vol. 52, no. supl., December 1998 (1998-12-01), pages 193 - 198, XP000909378 * |
Cited By (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1224930A1 (en) * | 2001-01-22 | 2002-07-24 | Pfizer Products Inc. | Combination of a SR inhibitor and sigma receptor ligand in the treatment ofdepression |
EP3610890A1 (en) | 2012-11-14 | 2020-02-19 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
US11344544B2 (en) | 2013-11-05 | 2022-05-31 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10080727B2 (en) | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9238032B2 (en) | 2013-11-05 | 2016-01-19 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
US9278095B2 (en) | 2013-11-05 | 2016-03-08 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9314462B2 (en) | 2013-11-05 | 2016-04-19 | Antecip Bioventures Ii Llc | Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects |
US9370513B2 (en) | 2013-11-05 | 2016-06-21 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9375429B2 (en) | 2013-11-05 | 2016-06-28 | Antecip Bioventures Ii Llc | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
US9402843B2 (en) | 2013-11-05 | 2016-08-02 | Antecip Bioventures Ii Llc | Compositions and methods of using threohydroxybupropion for therapeutic purposes |
US9402844B2 (en) | 2013-11-05 | 2016-08-02 | Antecip Bioventures Ii Llc | Methods of modulating drug plasma levels using erythrohydroxybupropion |
US9408815B2 (en) | 2013-11-05 | 2016-08-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9421176B1 (en) | 2013-11-05 | 2016-08-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9457023B1 (en) | 2013-11-05 | 2016-10-04 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9457025B2 (en) | 2013-11-05 | 2016-10-04 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
US9474731B1 (en) | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9486450B2 (en) | 2013-11-05 | 2016-11-08 | Antecip Bioventures Ii Llc | Hydroxybupropion and related compounds as modulators of drug plasma levels |
US9700528B2 (en) | 2013-11-05 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9700553B2 (en) | 2013-11-05 | 2017-07-11 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9707191B2 (en) | 2013-11-05 | 2017-07-18 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11969421B2 (en) | 2013-11-05 | 2024-04-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US9763932B2 (en) | 2013-11-05 | 2017-09-19 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9861595B2 (en) | 2013-11-05 | 2018-01-09 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9867819B2 (en) | 2013-11-05 | 2018-01-16 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9968568B2 (en) | 2013-11-05 | 2018-05-15 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10058518B2 (en) | 2013-11-05 | 2018-08-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10064857B2 (en) | 2013-11-05 | 2018-09-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11020389B2 (en) | 2013-11-05 | 2021-06-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10092561B2 (en) | 2013-11-05 | 2018-10-09 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
US10092560B2 (en) | 2013-11-05 | 2018-10-09 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10105361B2 (en) | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10105327B2 (en) | 2013-11-05 | 2018-10-23 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
US11779579B2 (en) | 2013-11-05 | 2023-10-10 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11628149B2 (en) | 2013-11-05 | 2023-04-18 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10251879B2 (en) | 2013-11-05 | 2019-04-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10463634B2 (en) | 2013-11-05 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10512643B2 (en) | 2013-11-05 | 2019-12-24 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10548857B2 (en) | 2013-11-05 | 2020-02-04 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US9198905B2 (en) | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
US10596167B2 (en) | 2013-11-05 | 2020-03-24 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
US11617747B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10772850B2 (en) | 2013-11-05 | 2020-09-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10780066B2 (en) | 2013-11-05 | 2020-09-22 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US11617728B2 (en) | 2013-11-05 | 2023-04-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10786469B2 (en) | 2013-11-05 | 2020-09-29 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10786496B2 (en) | 2013-11-05 | 2020-09-29 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10799497B2 (en) | 2013-11-05 | 2020-10-13 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
US10806710B2 (en) | 2013-11-05 | 2020-10-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11596627B2 (en) | 2013-11-05 | 2023-03-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10864209B2 (en) | 2013-11-05 | 2020-12-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10874663B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10874664B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10874665B2 (en) | 2013-11-05 | 2020-12-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10881624B2 (en) | 2013-11-05 | 2021-01-05 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
US10881657B2 (en) | 2013-11-05 | 2021-01-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10894046B2 (en) | 2013-11-05 | 2021-01-19 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10894047B2 (en) | 2013-11-05 | 2021-01-19 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10898453B2 (en) | 2013-11-05 | 2021-01-26 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11590124B2 (en) | 2013-11-05 | 2023-02-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10933034B2 (en) | 2013-11-05 | 2021-03-02 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11576909B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11058648B2 (en) | 2013-11-05 | 2021-07-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10966941B2 (en) | 2013-11-05 | 2021-04-06 | Antecip Bioventures Ii Llp | Bupropion as a modulator of drug activity |
US11576877B2 (en) | 2013-11-05 | 2023-02-14 | Antecip Bioventures Ii Llc | Bupropion as modulator of drug activity |
US10966974B2 (en) | 2013-11-05 | 2021-04-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10980800B2 (en) | 2013-11-05 | 2021-04-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11129826B2 (en) | 2013-11-05 | 2021-09-28 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
US9205083B2 (en) | 2013-11-05 | 2015-12-08 | Antecip Bioventures Ii Llc | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
US10945973B2 (en) | 2013-11-05 | 2021-03-16 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11065248B2 (en) | 2013-11-05 | 2021-07-20 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11090300B2 (en) | 2013-11-05 | 2021-08-17 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11096937B2 (en) | 2013-11-05 | 2021-08-24 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11123343B2 (en) | 2013-11-05 | 2021-09-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11123344B2 (en) | 2013-11-05 | 2021-09-21 | Axsome Therapeutics, Inc. | Bupropion as a modulator of drug activity |
US11571399B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11007189B2 (en) | 2013-11-05 | 2021-05-18 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11141388B2 (en) | 2013-11-05 | 2021-10-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11141416B2 (en) | 2013-11-05 | 2021-10-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11147808B2 (en) | 2013-11-05 | 2021-10-19 | Antecip Bioventures Ii Llc | Method of decreasing the fluctuation index of dextromethorphan |
US11571417B2 (en) | 2013-11-05 | 2023-02-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11185515B2 (en) | 2013-11-05 | 2021-11-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11191739B2 (en) | 2013-11-05 | 2021-12-07 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11197839B2 (en) | 2013-11-05 | 2021-12-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11207281B2 (en) | 2013-11-05 | 2021-12-28 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11213521B2 (en) | 2013-11-05 | 2022-01-04 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11541021B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11229640B2 (en) | 2013-11-05 | 2022-01-25 | Antecip Bioventures Ii Llc | Combination of dextromethorphan and bupropion for treating depression |
US11234946B2 (en) | 2013-11-05 | 2022-02-01 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11253492B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11253491B2 (en) | 2013-11-05 | 2022-02-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11273134B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11273133B2 (en) | 2013-11-05 | 2022-03-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11285146B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11285118B2 (en) | 2013-11-05 | 2022-03-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11291665B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11291638B2 (en) | 2013-11-05 | 2022-04-05 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11298352B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11298351B2 (en) | 2013-11-05 | 2022-04-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11541048B2 (en) | 2013-11-05 | 2023-01-03 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11311534B2 (en) | 2013-11-05 | 2022-04-26 | Antecip Bio Ventures Ii Llc | Bupropion as a modulator of drug activity |
US9168234B2 (en) | 2013-11-05 | 2015-10-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11357744B2 (en) | 2013-11-05 | 2022-06-14 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11364233B2 (en) | 2013-11-05 | 2022-06-21 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11382874B2 (en) | 2013-11-05 | 2022-07-12 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11419867B2 (en) | 2013-11-05 | 2022-08-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11426370B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11426401B2 (en) | 2013-11-05 | 2022-08-30 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11433067B2 (en) | 2013-11-05 | 2022-09-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11439636B1 (en) | 2013-11-05 | 2022-09-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11478468B2 (en) | 2013-11-05 | 2022-10-25 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11497721B2 (en) | 2013-11-05 | 2022-11-15 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11510918B2 (en) | 2013-11-05 | 2022-11-29 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11517542B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11517544B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11517543B2 (en) | 2013-11-05 | 2022-12-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11524008B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11524007B2 (en) | 2013-11-05 | 2022-12-13 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11534414B2 (en) | 2013-11-05 | 2022-12-27 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11129801B2 (en) | 2016-02-11 | 2021-09-28 | Sigmathera Sas | Igmesine for use in the treatment of neurodegenerative diseases |
CN109069414B (en) * | 2016-02-11 | 2022-01-14 | 西格马瑟拉公司 | Igemeine for the treatment of neurodegenerative diseases |
EP3903767A1 (en) | 2016-02-11 | 2021-11-03 | SigmaThera SAS | Igmesine for use in the treatment of neurodegenerative diseases |
WO2017137600A1 (en) | 2016-02-11 | 2017-08-17 | Sigmathera Sas | Igmesine for use in the treatment of neurodegenerative diseases |
CN109069414A (en) * | 2016-02-11 | 2018-12-21 | 西格马瑟拉公司 | For treating the Igmesine of neurodegenerative disease |
JP7059192B2 (en) | 2016-02-11 | 2022-04-25 | シグマテラ・ソシエテ・パ・アクシオンス・シンプリフィエ | Igmesin for use in the treatment of neurodegenerative diseases |
JP2019504872A (en) * | 2016-02-11 | 2019-02-21 | シグマテラ・ソシエテ・パ・アクシオンス・シンプリフィエ | Igumesin for use in the treatment of neurodegenerative diseases |
US10688066B2 (en) | 2018-03-20 | 2020-06-23 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for treating nicotine addiction |
US10813924B2 (en) | 2018-03-20 | 2020-10-27 | Antecip Bioventures Ii Llc | Bupropion and dextromethorphan for treating nicotine addiction |
US10780064B2 (en) | 2019-01-07 | 2020-09-22 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10925842B2 (en) | 2019-01-07 | 2021-02-23 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10940124B2 (en) | 2019-01-07 | 2021-03-09 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US10966942B2 (en) | 2019-01-07 | 2021-04-06 | Antecip Bioventures Ii Llc | Bupropion as a modulator of drug activity |
US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Also Published As
Publication number | Publication date |
---|---|
AU2180400A (en) | 2000-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000041684A1 (en) | A pharmaceutical combination for the treatment of depression | |
Hanotin et al. | Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study | |
Zajecka | {Clinical Issues in Long-Term Treatment With Antidepressants | |
Fabre et al. | Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo | |
US20050026977A1 (en) | Zonisamide use in eating disorders | |
JPH06102622B2 (en) | Treatment of obesity | |
CA2332253A1 (en) | Combination therapy for treatment of depression | |
EP1671628A1 (en) | Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | |
WO2010125348A1 (en) | Prevention and treatment of sarcopenia | |
US5939426A (en) | Methods for treating urinary incontinence using descarboethoxyloratadine | |
JPH0635382B2 (en) | Uses of fluoxetine as an anxiolytic | |
US20210353559A1 (en) | Composition and method for treating neurological disease | |
JP2004525940A (en) | Duloxetine for the treatment of hot flashes | |
Sasson et al. | Potentiation of morphine analgesia by d-amphetamine | |
Pilgrim | The clinical profile of sumatriptan: efficacy in migraine | |
EP1589958B1 (en) | Reduced dose of tolterodine for treating urinary disorders | |
US6589996B2 (en) | Treatment of disorders relating to the serotonergic system | |
CA2403350A1 (en) | Use of deramciclane for the treatment of anxiety and depression | |
Kim et al. | Open fixed dose trial of fluoxetine in the treatment of obsessive compulsive disorder | |
Parsons et al. | Darifenacin in the treatment of overactive bladder | |
JP2009007278A (en) | Remedy of fibromyalgia | |
JPH09165337A (en) | Remedy for panic disorder | |
JPS6241208B2 (en) | ||
Licciardello et al. | Amlodipine vs nifedipine: a crossover study of efficacy and tolerability in patients with stable angina pectoris | |
CN115813932A (en) | Novel medicine composition for treating major depressive disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |